论文部分内容阅读
目的:小肠癌是一种少见的消化道肿瘤,多数患者初诊时已无法手术切除或出现远处转移,因此化疗在小肠癌治疗中占有重要地位。本研究旨在评价FOLFOX和XELOX方案治疗晚期中国小肠癌患者的疗效及安全性。方法:对2004年1月～2010年1月期间,在中山大学肿瘤医院等3个中心所有接受过FOLFOX或XELOX方案化疗的34例晚期小肠癌患者进行了回顾性分析。利用SPSS13.0统计软件对方案的有效率(RR),无进展生存时间(PFS),总生存时间(OS)以及化疗相关的不良反应进行分析。结果:共纳入病例34例,其中28例接受了FOLFOX治疗,6例接受了XELOX方案治疗。客观有效率及疾病控制率分别为32.3%和61.7%。中位PFS和OS分别为6.3和14.2个月。化疗相关不良反应可耐受,3～4级不良反应发生率较少,其中1～2级纳差(58.8%)、恶心(47.1%)、外周神经毒性(41.2%)是最常见的反应。结论:本研究在国内首次报道了奥沙利铂联合氟尿嘧啶类方案治疗晚期小肠癌疗效,结果显示FOLFOX或XELOX方案治疗晚期小肠癌安全有效,该方案仍值得进一步研究。
Objective: Small intestine cancer is a rare gastrointestinal cancer, most patients have no surgical resection or distant metastasis at the time of initial diagnosis, so chemotherapy plays an important role in the treatment of small intestine cancer. This study was designed to evaluate the efficacy and safety of FOLFOX and XELOX regimens in the treatment of patients with advanced colorectal cancer in the advanced stage. Methods: From January 2004 to January 2010, 34 patients with advanced small intestine cancer who underwent chemotherapy with FOLFOX or XELOX regimen were retrospectively analyzed in 3 centers including Sun Yat-sen University Cancer Hospital. The effectiveness of the program (RR), progression-free survival time (PFS), overall survival time (OS), and chemotherapy-related adverse events were analyzed using SPSS 13.0 statistical software. RESULTS: A total of 34 patients were enrolled, of whom 28 received FOLFOX and 6 received XELOX. Objectively effective and disease control rates were 32.3% and 61.7% respectively. Median PFS and OS were 6.3 and 14.2 months, respectively. Chemotherapy-related adverse reactions were tolerable, and the incidence of grade 3 to 4 adverse reactions was less, of which grade 1 to 2 anorexia (58.8%), nausea (47.1%) and peripheral neurotoxicity (41.2%) were the most common reactions. CONCLUSIONS: This study reports for the first time in China the efficacy of oxaliplatin plus fluorouracil in the treatment of advanced small intestine cancer. The results show that FOLFOX or XELOX regimen is safe and effective for the treatment of advanced small intestine cancer. This study is still worth further study.